

March 2024 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW

DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Xdemvy (lotilaner)	For the treatment of Demodex blepharitis (DB)	Formulary	N/A

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 5/1/2024.

NEW INDICATIONS REVIEW

DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Jaypirca (pirtobrutinib) 50 & 100 mg tablets for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	Formulary	Formulary
Cresemba (isavuconazonium sulfate) 74.5 & 186 mg capsules and 372 mg vial for injection for invasive aspergillosis and invasive mucormycosis age expansion	Non-Formulary	Non-Formulary
Tarpeyo (budesonide) 4 mg DR capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN)	Formulary	Formulary
Adbry (tralokinumab) 150 mg/mL injection for subcutaneous administration for moderate-severe	Formulary	Formulary

March 2024 Pharmacy & Therapeutics Committee Decisions

atopic dermatitis age expansion		
Welireg (belzutifan) 40 mg tablets for advanced renal cell carcinoma (RCC)	Formulary	Formulary
Nexletol (bempedoic acid) 180 mg tablets and Nexlizet (bempedoic acid and ezetimibe) 180 mg-10 mg tablets for primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease (ASCVD) as an adjunct to statin therapy	Non-Formulary	Non-Formulary
Xtandi (enzalutamide) 40 mg capsules and 40 & 80 mg tablets for non-metastatic castration-sensitive prostate cancer	Formulary	Formulary
Hyqvia (human immune globulin) 100 mg/mL subcutaneous kits for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy	Formulary	Formulary
Piqray (alpelisib) 50, 150, & 200 mg tablets expanded approval for pre- and peri-menopausal women	Formulary	Formulary
Balversa (erdafitinib) 3,4, & 5 mg tablets for adults with locally advanced/metastatic urothelial carcinoma with FGFR3 genetic alterations after platinum-containing chemotherapy	Formulary	Formulary
Dupixent (dupilumab) 200 mg/1.14 mL and 300 mg/2 mL injections for eosinophilic esophagitis in patients \geq 1 year age expansion	Formulary	Formulary

NEW GENERICS REVIEW

DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
------	-----------------------	----------------

March 2024 Pharmacy & Therapeutics Committee Decisions

Cyanocobalamin (Nascobal) 500 mcg/0.1 mL nasal spray vitamin B12 therapy	Non-Formulary	Non-Formulary
Podofilox (Condylox) 0.5% gel for anogenital warts	Podofilox solution is available on formulary	Non-Formulary
Insulin glargine (Toujeo AG) 300 unit/mL pen-injector for diabetes	Medicare includes Toujeo on the \$35 insulin program	Non-Formulary
Dapagliflozin (Farxiga AG) 5 & 10 mg tablets for type 2 diabetes, heart failure, & chronic kidney disease	Multisource brand product. True generic expected end of 2025	Non-Formulary
Dapagliflozin-metformin ER (Xigduo XR AG) 5-1000 & 10-1000 mg tablets for type 2 diabetes	Multisource brand product. True generic expected end of 2025	Non-Formulary
Bromfenac (Prolensa) 0.07% ophthalmic solution for postoperative inflammation & ocular pain	Non-Formulary	Non-Formulary
Indomethacin (Indocin) 25 mg/5 mL oral suspension for pain	Non-Formulary	Non-Formulary
Udenyca Onbody (pegfilgrastim) 6 mg/0.6 mL syringe for febrile neutropenia	Udenyca covered. Onbody injector must be filled by a healthcare provider.	Non-Formulary
Gabapentin (Gralise) 300 & 600 mg tablets for postherpetic neuralgia	At over \$9 per tablet, the generic Gralise is still 60-90 times the cost of the generic tablets.	Non-Formulary
mifepristone (Korlym) 300 mg tablet for hyperglycemia secondary to hypercortisolism	Medicare covers Brand Korlym	Formulary

MISCELLANEOUS PREVIOUSLY REVIEWED ITEMS

DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
------	-----------------------	----------------

March 2024 Pharmacy & Therapeutics Committee Decisions

<p>Prolia (denosumab) 60 mg/mL injection</p>	<ul style="list-style-type: none"> • new boxed warning for severe hypocalcemia in those with advanced chronic kidney disease (CKD) • Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported • CKD-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia 	<p>Non-Formulary</p>
<p>Paxlovid</p>	<ul style="list-style-type: none"> • FDA announced all Paxlovid (nirmatrelvir/ritonavir) labeled for emergency use authorization (EUA) will no longer be authorized for use after 3/8/24 regardless of expiration date • The transition to commercialized, non-government supplied product will be complete 	<p>Formulary</p>
<p>Novo Nordisk Levemir (insulin detemir) and Glucagen HypoKit (glucagon)</p>	<ul style="list-style-type: none"> • Novo Nordisk is discontinuing Levemir (insulin detemir) and GlucaGen HypoKit (glucagon) • Global manufacturing constraints, formulary losses impacting patient access, and availability of alternatives are cited for the product discontinuations • Levemir FlexPen will be discontinued on April 1, 2024 and the 10 mL vial will be discontinued on December 31, 2024, although supply disruptions may occur earlier • GlucaGen HypoKit will be discontinued on July 1, 2024 	<p>Levemir – Non-Formulary Glucagen HypoKit – Non-Formulary</p>

ADDITIONAL ITEMS REVIEWED

ITEM	DRUGS WITH NEW POLICIES
------	-------------------------

March 2024 Pharmacy & Therapeutics Committee Decisions

New Medical Drug Policies (effective 05/15/2024)	<ul style="list-style-type: none">• Wainua• Lyfgenia• Casgevy• Amtagvi• iDose TR
---	--